Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenues	$ 0	$ 0
Operating expenses:
Research and development	3,435	4,252
General and administrative	2,477	2,393
Depreciation and amortization	31	32
Total operating expenses	5,943	6,677
Loss from operations	(5,943)	(6,677)
Other income (loss):
Gain from change in fair value of warrant liability	9,054	1,455
Transaction costs allocated to warrant liabilities	(1,788)	0
Loss on issuance of warrant liabilities	(7,798)	0
Other income, net	9	11
Interest income, net	30	241
Net loss	$ (6,436)	$ (4,970)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.69)	$ (2.02)
Weighted average common shares outstanding, basic and diluted (in shares)	9,343,771	2,466,174
Net loss	$ (6,436)	$ (4,970)
Other comprehensive income (loss):
Foreign currency translation	3	(9)
Comprehensive loss	$ (6,433)	$ (4,979)